This bill requires the Food and Drug Administration (FDA) to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.
The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2018-04-12 | IntroReferral | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. | Senate |
| 2018-04-12 | IntroReferral | Introduced in Senate | Library of Congress |